For the new penny stock investors, there are two tips need to remember before buying any penny stocks. Number one, they are risky, there is always a reason why a company’s stock price less than $5. you can find it out through research the details from the company. Number two, even a fluctuation of just 5 cents up or down over the course of a day that can makes you totally lose all your money. so, you need to due diligence before jumping into the penny stock market.

if you can't find out those stocks growth potential, you could following the most active or popular names in the market, such Sundial Growers, Zomedica or Nokia. there must have been some good or bad news when they are always exposed. you can find investment potential out with these penny stocks. there are two more active names on this list, let’s talk about them.


Dynatronics Corporation (DYNT)

Industry: Medical Equipment & Supplies

Market Cap: 23.96M

Price: $1.60 (as of Feb 25)

Dynatronics Corporation is a leading manufacturer of athletic training, physical therapy, and rehabilitation products. The announcement on late yesterday  that its wholly-owned subsidiary, Bird & Cronin, LLC, renewed its purchasing agreement with Intalere, one of the leading national group purchasing organizations in the healthcare industry. The new agreement which extends the partnership through January 2024. That why DYNT stock price increases over 120% pre-market yesterday. 

The stock seems be a promising investment opportunity at the moment. with the continued relationship with Intalere. the revenue of the company will continued on the upward trend. pushing the company closer and closer to profitability. All in all, DYNT stock is worth to watch for penny stock investors.

Obseva SA (OBSV)

Industry: Biotechnology & Drugs

Market Cap: 214.01M

Price: $3.89 (as of Feb 25)

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Several research analysts have recently issued reports about the stock and raised shares of the company from a “sell” rating to a “hold” or  a “buy” rating. And several hedge funds and other investors also have recently made changes to their positions in OBSV stock, includes Cutter & CO Brokerage Inc, GSA Capital Partners LLP and Jane Street Group LLC. All in all, OBSV is the stock worth to watch for investors next week.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.